Genetic variation in cholinergic muscarinic-2 receptor gene modulates M 2 receptor binding in vivo and accounts for reduced binding in bipolar disorder

Molecular Psychiatry

Volumn 16, Issue 4, 2011, Pages 407-418

  Cannon, D M ^a,b   Klaver, J K ^b   Gandhi, S K ^b   Solorio, G ^b   Peck, S A ^b   Erickson, K ^b   N Akula, J S ^b   Eckelman, W C ^c   Furey, M L ^b   Sahakian, B J ^d   McMahon, F J ^b   Drevets, W C ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Molecular Tracer LLC   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

18F FP TZTP; CHRM2; depression; G protein coupled receptor; muscarinic M2 binding; PET

Indexed keywords

ADENINE; FLUORINE 18; MUSCARINIC M2 RECEPTOR; THYMINE;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR DEPRESSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECOGNITION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS; SUICIDE ATTEMPT;

ADOLESCENT; ADULT; BIPOLAR DISORDER; BRAIN; COGNITION DISORDERS; FEMALE; FLUORINE RADIOISOTOPES; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, MUSCARINIC M2; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 79953043833     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2010.24     Document Type: Article

References (94)

1. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006; 63: 741-747.
2. 18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neurophar-macology 2003; 44: 653-661. (Pubitemid 36372054)
3. 18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab 1998; 18: 1130-1142. (Pubitemid 28465361)
4. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S et al. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 2004; 13: 1903-1911. (Pubitemid 39214338)
5. Comings DE, Wu S, Rostamkhani M, McGue M, Iacono WG, MacMurray JP. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet 2002; 114: 527-529. (Pubitemid 34680580)
6. Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 2005; 14: 2421-2434. (Pubitemid 41418004)
7. Cohen-Woods S, Gaysina D, Craddock N, Farmer A, Gray J, Gunasinghe C et al. Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. Hum Mol Genet 2009; 18: 1504-1509.
8. Saffen D, Mieda M, Okamura M, Haga T. Control elements of muscarinic receptor gene expression. Life Sci 1999; 64: 479-486. (Pubitemid 29066696)
9. Detera-Wadleigh SD, Badner JA, Yoshikawa T, Sanders AR, Goldin LR, Turner G et al. Initial genome scan of the NIMH genetics initiative bipolar pedigrees: chromosomes 4, 7, 9, 18, 19, 20, and 21q. Am J Med Genet 1997; 74: 254-262. (Pubitemid 27251223)
10. Detera-Wadleigh SD, Badner JA, Berrettini WH, Yoshikawa T, Goldin LR, Turner G et al. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci USA 1999; 96: 5604-5609. (Pubitemid 29234665)
11. Liu J, Juo SH, Dewan A, Grunn A, Tong X, Brito M et al. Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Mol Psychiatry 2003; 8: 333-342. (Pubitemid 36712927)
12. Dick DM, Aliev F, Wang JC, Grucza RA, Schuckit M, Kuperman S et al. Using dimensional models of externalizing psychopathology to aid in gene identification. Arch Gen Psychiatry 2008; 65: 310-318. (Pubitemid 351342447)
13. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008; 213: 93-118.
14. Gourovitch ML, Torrey EF, Gold JM, Randolph C, Weinberger DR, Goldberg TE. Neuropsychological performance of monozygotic twins discordant for bipolar disorder. Biol Psychiatry 1999; 45: 639-646. (Pubitemid 29147374)
15. Keri S, Kelemen O, Benedek G, Janka Z. Different trait markers for schizophrenia and bipolar disorder: a neurocognitive approach. Psychol Med 2001; 31: 915-922. (Pubitemid 32621900)
16. MacQueen GM, Galway TM, Hay J, Young LT, Joffe RT. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol Med 2002; 32: 251-258. (Pubitemid 34162583)
17. Jones KA, Porjesz B, Almasy L, Bierut L, Dick D, Goate A et al. A cholinergic receptor gene (CHRM2) affects event-related oscillations. Behav Genet 2006; 36: 627-639. (Pubitemid 44188078)
18. Jones KA, Porjesz B, Almasy L, Bierut L, Goate A, Wang JC et al. Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: implications for human brain dynamics and cognition. Int J Psychophysiol 2004; 53: 75-90. (Pubitemid 38798350)
19. Rangaswamy M, Porjesz B. Uncovering genes for cognitive (dys)function and predisposition for alcoholism spectrum disorders: a review of human brain oscillations as effective endophenotypes. Brain Res 2008; 1235: 153-171.
20. Basar E, Basar-Eroglu C, Karakas S, Schurmann M. Are cognitive processes manifested in event-related gamma, alpha, theta and delta oscillations in the EEG? Neurosci Lett 1999; 259: 165-168. (Pubitemid 29059610)
21. Schurmann M, Basar-Eroglu C, Kolev V, Basar E. Delta responses and cognitive processing: single-trial evaluations of human visual P300. Int J Psychophysiol 2001; 39: 229-239. (Pubitemid 32041269)
22. Mitrofanis J, Guillery RW. New views of the thalamic reticular nucleus in the adult and the developing brain. Trends Neurosci 1993; 16: 240-245. (Pubitemid 23139189)
23. Basar E, Basar-Eroglu C, Karakas S, Schurmann M. Gamma, alpha, delta, and theta oscillations govern cognitive processes. Int J Psychophysiol 2001; 39: 241-248. (Pubitemid 32041270)
24. Doppelmayr M, Klimesch W, Schwaiger J, Auinger P, Winkler T. Theta synchronization in the human EEG and episodic retrieval. Neurosci Lett 1998; 257: 41-44. (Pubitemid 28546900)
25. Gevins A, Smith ME, Leong H, McEvoy L, Whitfield S, Du R et al. Monitoring working memory load during computer-based tasks with EEG pattern recognition methods. Human Factors 1998; 40: 79-91. (Pubitemid 28194524)
26. Klimesch W, Doppelmayr M, Yonelinas A, Kroll NE, Lazzara M, Rohm D et al. Theta synchronization during episodic retrieval: neural correlates of conscious awareness. Brain Research 2001; 12: 33-38. (Pubitemid 32728278)
27. Klimesch W, Schimke H, Schwaiger J. Episodic and semantic memory: an analysis in the EEG theta and alpha band. Electro-encephalogr Clin Neurophysiol 1994; 91: 428-441.
28. Dick DM, Aliev F, Kramer J, Wang JC, Hinrichs A, Bertelsen S et al. Association of CHRM2 with IQ: converging evidence for a gene influencing intelligence. Behav Genet 2007; 37: 265-272. (Pubitemid 46425336)
29. Gosso FM, de Geus EJ, Polderman TJ, Boomsma DI, Posthuma D, Heutink P. Exploring the functional role of the CHRM2 gene in human cognition: results from a dense genotyping and brain expression study. BMC Med Genet 2007; 8: 66.
30. Gosso MF, van Belzen M, de Geus EJ, Polderman JC, Heutink P, Boomsma DI et al. Association between the CHRM2 gene and intelligence in a sample of 304 Dutch families. Genes Brain Behav 2006; 5: 577-584. (Pubitemid 44665355)
31. Comings DE, Wu S, Rostamkhani M, McGue M, Lacono WG, Cheng LS et al. Role of the cholinergic muscarinic 2 receptor (CHRM2) gene in cognition. Mol Psychiatry 2003; 8: 10-11. (Pubitemid 36188566)
32. Posthuma D, Luciano M, Geus EJ, Wright MJ, Slagboom PE, Montgomery GW et al. A genomewide scan for intelligence identifies quantitative trait loci on 2q and 6p. Am J Hum Genet 2005; 77: 318-326. (Pubitemid 41022713)
33. Janowsky DS, el-Yousef K, Davis JM, Sekerke HJ. Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry 1973; 28: 542-547.
34. Janowsky DS, el-Yousef MK, Davis JM. Acetylcholine and depression. Psychosom Med 1974; 36: 248-257.
35. Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. Lancet 1972a; 1: 1236-1237.
36. Gillin JC, Sitaram N, Duncan WC. Muscarinic supersensitivity: a possible model for the sleep disturbance of primary depression? Psychiatry Res 1979; 1: 17-22. (Pubitemid 10124709)
37. Gillin JC, Sitaram N, Mendelson WB. Acetylcholine, sleep, and depression. Hum Neurobiol 1982; 1: 211-219.
38. Risch SC, Janowsky DS, Gillin JC. Muscarinic supersensitivity of anterior pituitary ACTH and B-endorphin release in major depressive illness. Peptides 1983b; 4: 789-792. (Pubitemid 14223732)
39. Risch SC, Janowsky DS, Gillin JC, Rausch JL, Loevinger BL, Huey LY. Muscarinic supersensitivity of anterior pituitary ACTH release in major depressive illness, adrenal cortical dissociation. Psycho-pharmacol Bull 1983c; 19: 343-346. (Pubitemid 13043617)
40. Risch SC, Janowsky DS, Mott MA, Gillin JC, Kalir HH, Huey LY et al. Central and peripheral cholinesterase inhibition: effects on anterior pituitary and sympathomimetic function. Psychoneur-oendocrinology 1986; 11: 221-230. (Pubitemid 16099996)
41. Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates. J Clin Psychopharmacol 1981; 1: 186-192. (Pubitemid 11025955)
42. Janowsky D, Overstreet D. The role of acetylcholine mechanisms in affective disorders. In: Floyd E Bloom and David J (eds). Psychopharmacology, The Fourth Generation of Progress. Kupfer Lippincott Williams and Wilkins, Raven Press: Nashville, TN, USA, 2000.
43. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972b; 2: 632-635.
44. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Sitaram N, Gillin JC et al. Physostigmine induction of depressive symptomatology in normal human subjects. Psychiatry Res 1981a; 4: 89-94. (Pubitemid 11131781)
45. Riemann D, Hohagen F, Bahro M, Lis S, Stadmuller G, Gann H et al. Cholinergic neurotransmission, REM sleep and depression. J Psychosom Res 1994; 38(Suppl 1): 15-25.
46. Dilsaver SC. Pathophysiology of 'cholinoceptor supersensitivity' in affective disorders. Biol Psychiatry 1986; 21: 813-829. (Pubitemid 16044005)
47. McGaugh JL. The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neu-rosci 2004; 27: 1-28. (Pubitemid 39050395)
48. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 2003; 54: 515-528. (Pubitemid 37289438)
49. Ketter TA, Andreason PJ, George MS, Lee C, Gill DS, Parekh PI et al. Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Arch Gen Psychiatry 1996; 53: 59-69. (Pubitemid 26015397)
50. Benson BE, Carson RE, Kiesewetter DO, Herscovitch P, Eckelman WC, Post RM et al. A potential cholinergic mechanism of procaine's limbic activation. Neuropsychopharmacology 2004; 29: 1239-1250. (Pubitemid 38780647)
51. Langer SZ. 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci 1997; 18: 95-99. (Pubitemid 27145735)
52. 11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007; 62: 870-877. (Pubitemid 47488222)
53. Burk JA, Sarter M. Dissociation between the attentional functions mediated via basal forebrain cholinergic and GABAergic neurons. Neuroscience 2001; 105: 899-909. (Pubitemid 32786803)
54. McGaughy J, Everitt BJ, Robbins TW, Sarter M. The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. Behav Brain Res 2000; 115: 251-263.
55. Sarter M, Bruno JP. Abnormal regulation of corticopetal choliner-gic neurons and impaired information processing in neuro-psychiatric disorders. Trends Neurosci 1999; 22: 67-74. (Pubitemid 29125553)
56. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Brit J Psychiat 1979; 134: 382-389. (Pubitemid 9136500)
57. Hamilton M. The assessment of anxiety states by rating. Brit J Med Psychol 1959; 32: 50-55.
58. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435. (Pubitemid 9006756)
59. Hollingshead A. Four Factor Index of Social Status. Department of Sociology, Yale University: New Haven (Connecticut), 1975. NIMH Genetics Initiative. Family interview for genetic studies. http://nimhgenetics.org/.
60. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814.
61. Gunderson KL, Kruglyak S, Graige MS, Garcia F, Kermani BG, Zhao C et al. Decoding randomly ordered DNA arrays. Genome Res 2004; 14: 870-877. (Pubitemid 38660504)
62. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet 2000; 67: 170-181. (Pubitemid 30481554)
63. 18F]FP-TZTP. Nucl Med Biol 2003; 30: 73-77.
64. Ma Y, Kiesewetter DO, Jagoda EM, Huang BX, Eckelman WC. Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-me thylpyridine, produced by human and rat hepatocytes. J Chromatogr B Biomed Sci Appl 2002; 766: 319-329. (Pubitemid 34142364)
65. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002; 15: 870-878. (Pubitemid 34852500)
66. 11C]DASB. International Journal of Neuropsychopharmacology 2009; 1-10; e-pub ahead of print (PMID 20047709).
67. Yan Z, Surmeier DJ. Muscarinic (m2/m4) receptors reduce N- and P-type Ca2 \+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway. J Neu-rosci 1996; 16: 2592-2604.
68. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Blockade of M2-like muscarinic receptors enhances long-term potentiation at corticostriatal synapses. Eur J Neurosci 1998; 10: 3020-3023. (Pubitemid 29073975)
69. Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009; 116: 184-191.
70. Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 2005; 65: 397-403.
71. Ross E. Pharmacodynamics. In: Hardman JG, Limbird LE, Gilman AG, (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edn. McGraw-Hill Professional: New York, NY, 1996.
72. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987; 237: 527-532. (Pubitemid 17125922)
73. Peralta EG, Winslow JW, Peterson GL, Smith DH, Ashkenazi A, Ramachandran J et al. Primary structure and biochemical properties of an M2 muscarinic receptor. Science 1987; 236: 600-605. (Pubitemid 17069932)
74. Bejerano G, Lowe CB, Ahituv N, King B, Siepel A, Salama SR et al. A distal enhancer and an ultraconserved exon are derived from a novel retroposon. Nature 2006; 441: 87-90.
75. Han JS, Boeke JD. LINE-1 retrotransposons: modulators of quantity and quality of mammalian gene expression? Bioessays 2005; 27: 775-784. (Pubitemid 41297400)
76. Hellmann-Blumberg U, Hintz MF, Gatewood JM, Schmid CW. Developmental differences in methylation of human Alu repeats. Mol Cell Biol 1993; 13: 4523-4530. (Pubitemid 23220359)
77. Muratani K, Hada T, Yamamoto Y, Kaneko T, Shigeto Y, Ohue T et al. Inactivation of the cholinesterase gene by Alu insertion: possible mechanism for human gene transposition. Proc Natl Acad Sci USA 1991; 88: 11315-11319. (Pubitemid 21916031)
78. McClintock B. The origin and behavior of mutable loci in maize. Proc Natl Acad Sci USA 1950; 36: 344-355.
79. Krejci A, Bruce AW, Dolezal V, Tucek S, Buckley NJ. Multiple promoters drive tissue-specific expression of the human M muscarinic acetylcholine receptor gene. J Neurochem 2004; 91: 88-98. (Pubitemid 39314940)
80. Heinzen EL, Ge D, Cronin KD, Maia JM, Shianna KV, Gabriel WN et al. Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol 2008; 6: e1.
81. Luo X, Kranzler HR, Zuo L, Zhang H, Wang S, Gelernter J. CHRM2 variation predisposes to personality traits of agreeableness and conscientiousness. Hum Mol Genet 2007; 16: 1557-1568. (Pubitemid 47050669)
82. Allen MH, Chessick CA, Miklowitz DJ, Goldberg JF, Wisniewski SR, Miyahara S et al. Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. Suicide Life Threat Behav 2005; 35: 671-680. (Pubitemid 43161558)
83. Taylor Tavares JV, Clark L, Cannon DM, Erickson K, Drevets WC, Sahakian BJ. Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression. Biol Psychiatry 2007; 62: 917-924. (Pubitemid 47488228)
84. Tavares JV, Drevets WC, Sahakian BJ. Cognition in mania and depression. Psychol Med 2003; 33: 959-967. (Pubitemid 37009814)
85. Roiser JP, Cannon DM, Gandhi SK, Taylor Tavares J, Erickson K, Wood S et al. Hot and cold cognition in unmedicated depressed subjects with bipolar disorder. Bipolar Disord 2009; 11: 178-189.
86. Holmes M, Erickson K, Luckenbaugh D, Drevets W, Bain E, Cannon D et al. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disorder 2008; 10: 806-815.
87. Elliott R, Sahakian B, Charney D. State of Science Review: E7. The Neural Basis of Resilience. Foresight Mental Capital and Well-being Project, 2008; http://www.foresight.gov.uk/; Government Office for Science, UK.
88. Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive reserve in neuropsychiatry. Psychol Med 2006; 36: 1053-1064. (Pubitemid 44084009)
89. Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2009; e-pub ahead of print July 27, 2009.
90. Schosser A, Cohen-Woods S, Gaysina D, Chow PC, Martucci L, Farmer A et al. NRG1 gene in recurrent major depression: no association in a large-scale case-control association study. Am J Med Genet B Neuropsychiatr Genet 2009; 153B: 141-147.
91. Giovannini MG. The role of the extracellular signal-regulated kinase pathway in memory encoding. Rev Neurosci 2006; 17: 619-634. (Pubitemid 46144732)
92. Power AE, Roozendaal B, McGaugh JL. Glucocorticoid enhancement of memory consolidation in the rat is blocked by muscarinic receptor antagonism in the basolateral amygdala. Eur J Neurosci 2000; 12: 3481-3487.
93. Clark L, Chamberlain SR, Sahakian BJ. Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 2009; 32: 57-74.
94. Erickson K, Drevets WC, Clark L, Cannon DM, Bain EE, Zarate Jr CA et al. Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry 2005; 162: 2171-2173. (Pubitemid 41598273)